Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Breast Cancer
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1378248
This article is part of the Research Topic Multidisciplinary and Personalized Approach in the Treatment of Advanced Breast Cancer View all 7 articles

Sacituzumab Govitecan response in extensive leptomeningeal carcinomatosis from Triple Negative Breast Cancer: A case report

Provisionally accepted
JESUS G. YARINGAÑO CERNA JESUS G. YARINGAÑO CERNA 1,2*MARIA ROCA HERRERA MARIA ROCA HERRERA 1SIMEON EREMIEV EREMIEV SIMEON EREMIEV EREMIEV 1PAU MASCARO BASELGA PAU MASCARO BASELGA 1PAU BENITO BUCH PAU BENITO BUCH 1FIDEL NUÑEZ MARIN FIDEL NUÑEZ MARIN 1Sergi Benavente Sergi Benavente 1ISABEL PIMENTEL ISABEL PIMENTEL 1,2
  • 1 Vall d'Hebron University Hospital, Barcelona, Spain
  • 2 Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Catalonia, Spain

The final, formatted version of the article will be published soon.

    Sacituzumab Govitecan (SG), a Trop-2-directed antibody-drug conjugate (ADC), was the first ADC approved for patients with metastatic triple negative breast cancer (mTNBC) who had received at least two prior lines of therapy for advanced disease. Although SG has shown promising clinical activity in treating brain metastases in both ASCENT randomized trial and real-world analysis, its utility in leptomeningeal carcinomatosis (LC) remains underexplored. We report the diagnostic and therapeutic process of a patient, who develops extensive LC from TNBC treated with SG. She presented clinical response after the first cycle of SG with a PFS of 6 months. This case report highlights the need for further inquiry into the use of SG in LC.

    Keywords: Triple negative breast cancer, Leptomeningeal carcinomatosis, Antibody-drug conjugate, Sacituzumab govitecan, partial response

    Received: 29 Jan 2024; Accepted: 24 Jul 2024.

    Copyright: © 2024 YARINGAÑO CERNA, ROCA HERRERA, EREMIEV EREMIEV, MASCARO BASELGA, BENITO BUCH, NUÑEZ MARIN, Benavente and PIMENTEL. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: JESUS G. YARINGAÑO CERNA, Vall d'Hebron University Hospital, Barcelona, Spain

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.